Abstract: Compositions including a quinolone component in an amount effective as an antibiotic when the composition is placed in a mammalian eye, and a carrier component in an amount effective to act as a carrier for the quinolone component are provided. The present compositions are substantially free of other components effective as preservatives. Preferably the quinolone component has fungistatic activity. In one very useful embodiment, the compositions include a NSAID component in an amount effective to reduce inflammation or pain when the composition is placed in a mammalian eye. Methods of using the present compositions, for example, to resolve microbial infections and/or to reduce inflammation and/or pain in a mammalian eye are included within the scope of the present invention.

Abstract: The present invention provides a method of providing neuroprotection to a mammal comprising administering to said mammal suffering from or at risk of suffering a noxious action on its nerve cells an effective amount of a compound of formula I to inhibit or prevent nerve cell injury or death 1

Abstract: The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I; 1

Abstract: Methods for treating a non-spasm caused pain by peripheral administration to a patient of a therapeutically effective amount of a neurotoxin, such as a botulinum toxin.

Abstract: The present invention relates to an agent comprising a neurotoxin, methods for making the agents and methods for treating endocrine disorders, for example gonadotrophin related illnesses. Preferably, the agent comprises at least a portion of a botulinum toxin.

Abstract: The present invention provides novel compounds represented by the general formula I.

Abstract: Intraocular lenses include an optic adapted to focus light toward a retina of an eye and a movement assembly coupled to the optic. In one embodiment, the optic has a far vision correction power and the movement assembly is adapted to cooperate with the eye to effect accommodating movement of the optic, preferably upon radial compression by a capsular bag of the eye. The optic preferably vaults anteriorly relative to the movement assembly. The movement assembly preferably circumscribes the optic and includes a member having a proximal end portion coupled to the optic and a distal end portion extending away from the optic and adapted to contact a capsular bag of the eye.

Abstract: Compounds of formula (i) and of formula (ii) 1

Abstract: Compounds having adrenergic activity which are a selective agonists for one or both of the &agr;2B and &agr;2c adrenoceptor receptor subtypes in preference to the &agr;2A adrenoceptor receptor subtype; the active compound being selected from the group consisting of compounds having the formula 1

Abstract: An binocular lens system for improving the vision of a patient including first and second ophthalmic lenses. Each of these lenses is adapted for implantation in an eye or to be disposed on or in the cornea. The first lens has a first baseline diopter power for distance vision correction and the second ophthalmic lens has a second baseline diopter power for other than distance vision correction. The ophthalmic lenses may be intraocular lenses which are implanted in the eyes of a patient or has natural lenses or following removal of the natural lenses.

Abstract: Apparatus for holding intraocular lenses and apparatus for holding intraocular lens injectors are provided which provide convenient and effective packaging systems for intraocular lenses and allow convenient and effective transfer of an intraocular lens to an injector in preparation for insertion of the intraocular lens into an eye.

Abstract: A method for treating hypothyroidism by local administration of a neurotoxin, such as a botulinum toxin, to a thyroid, thereby reducing an inhibitory effect upon thyroid hormone secretion. A method for treating hyperthyroidism by local administration of a neurotoxin, such as a botulinum toxin, to a sympathetic ganglion which innervates the thyroid, thereby reducing a stimulatory effect upon thyroid hormone secretion. Methods for treating calcium metabolism disorders by local administration of a neurotoxin to modulate calcitonin secretion are also disclosed.

Abstract: A scleral implant includes a body with a central portion and a pair of end portions. Each of the portions has a parametrical dimension. The parametrical dimension of the central portion is greater than the parametrical dimensions of each of the end portions. Accordingly, when the implant is positioned within an incision in the sclera of an eye, the inward force of the incision on the central portion of the body frictionally retains the implant within the incision. The scleral implant may include one or more enlarged portions each having a parametrical dimension greater than the parametrical dimension of the central portion. The implant may structure for engaging with sides of the incision such that extrusion of the implant from the incision is mitigated. The structure may include a plurality of dimples or a plurality of nodes formed in the surface of the body. Each of these structures forms a discontinuity or a purchase on the body to which post-operative cellular and fibrous growth may attached.

Abstract: Intraocular lenses include a reduced size optic adapted to focus light toward a retina of an eye and an at least partially opaque movement assembly coupled to the optic. In one embodiment, the optic has a far vision correction power and the movement assembly is at least partially black and adapted to cooperate with the eye to effect accommodating movement of the optic, preferably upon radial compression by a capsular bag of the eye. The optic preferably vaults anteriorly relative to the movement assembly. Enhanced amounts of accommodation preferably are achieved. Combinations of first and second optics and at least partially opaque movement assembly are also provided.

Abstract: A pharmaceutical composition for the controlled release of therapeutic agents from carboxylic acid ortho ester polymers contains a pharmaceutically acceptable salt of an acid, which together with the acid R1-COOH liberated from the decomposition of the ortho ester polymer forms a buffer system in a physiologically acceptable pH range.

Abstract: The present invention provides a method of providing neuroprotection to a mammal comprising administering to said mammal suffering from or at risk of suffering a noxious action on its nerve cells an effective amount of a compound of formula I to inhibit or prevent nerve cell injury or death 1

Abstract: Methods for treating conditions in an animal or human subject. The conditions may be pain, skeletal muscle conditions, smooth muscle conditions, glandular conditions and cosmetic conditions. The methods comprise the step of administering a Clostridium neurotoxin component or Clostridium neurotoxin component encoding DNA to the subject using a needleless syringe.